

# symposium article

*Annals of Oncology* 23 (Supplement 10): x197–x203, 2012  
doi:10.1093/annonc/mds319

## Going beyond EGFR

S. Zimmermann & S. Peters\*

Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland

A substantial proportion of non-small-cell lung cancer (NSCLC), and adenocarcinoma in particular, depends on a so-called ‘driver mutation’ for their malignant phenotype. This genetic alteration induces and sustains tumorigenesis, and targeting of its protein product can result in growth inhibition, tumor response and increased patient survival. NSCLC can thus be subdivided into clinically relevant molecular subsets. Mutations in *EGFR* best illustrate the therapeutic relevance of molecular classification. This article reviews the scope of presently known driving molecular alterations, including *ROS1*, *BRAF*, *KRAS*, *HER2* and *PIK3CA*, with a special emphasis on *ALK* rearrangements, and outlines their potential therapeutic applications.

**Key words:** driver mutations, lung cancer, oncogenic pathways

### introduction

Distinct subtypes of non-small-cell lung cancer (NSCLC) are driven by a specific genetic alteration—are so-called ‘oncogene addicted’—and are thus sensitive to inhibition of the corresponding activated oncogenic pathway. This new paradigm has substantially impacted lung cancer treatment: early treatment of advanced NSCLC consisted of chemotherapy tailored for patients according to the expected toxicity and more recently according to the histologic subtype [1]. Nowadays, NSCLC can be further subdivided into clinically relevant molecular subsets, according to their driving genetic alterations affecting tumor proliferation and survival. Treatment of patients with *EGFR* activating and sensitizing mutation-driven NSCLC with *EGFR* tyrosine kinase inhibitors (TKIs) results in an unprecedented response rate (RR) of 60–80%, a median progression-free survival (PFS) of ~8–13 months, as well as an improved quality of life compared with chemotherapy [2, 3]. Tumor genotype analysis has to date identified driver alterations in ~50–80% of NSCLC patients according to demographics, and particularly ethnicity. Sequist et al. [4] carried out a multiplexed PCR-based assay to simultaneously identify >50 mutations in several key NSCLC genes on parallel to FISH analysis for *EML4-ALK* translocations on 552 tumors mainly from Caucasian smoker patients. Eighty-one percent were adenocarcinomas, and a genetic driver change was identified in 51% of all samples, most commonly *KRAS* (24%), *EGFR* (13%) and *EML4-ALK* translocation (5%). Less common mutations were also identified: *TP53* (4%), *PI3KCA* (2%), *beta-catenin* (2%), *BRAF* (1%), *NRAS* (1%), *HER2* (~1%) and *IDH1* (~1%). A Chinese surgical series by Sun et al. [5] examined a genotyping panel of mutations in 52 resected lung adenocarcinomas from East

Asian never smokers and found 90% of tumors to be harboring a mutation in *EGFR*, *KRAS*, *ALK* or *HER2*. Focusing on adenocarcinoma subtype, the NCI’s Lung Cancer Mutation Consortium (LCMC) tested 830 patients with lung adenocarcinoma, and detected a driver mutation in 54%: *KRAS* 25%, *EGFR* 23%, *BRAF* 3%, *PIK3CA* 3%, *HER2* 1%, *MEK1* 0.4%, *NRAS* 0.2%, *ALK* rearrangements 6% and *MET* amplifications 2% [6].

Takeuchi et al. [7] identified *KIF5B-ALK* fusions in ~0.2% of resected adenocarcinomas, *ROS1* gene rearrangements with five different fusion partners: *TPM3*, *SDC4*, *SLC34A2*, *CD74* and *E2R* in 1.2% of adenocarcinomas and *CCDC6-RET* in an extremely small minority of adenocarcinomas. Kohno et al. [8] identified *KIF5B-RET* fusions in ~1.9% of adenocarcinomas (patients of Japanese ancestry). At ASCO 2012, Capelletti et al. reported on 11 patients with *KIF5B-RET* fusions among 643 patients [9]. More recently, Togashi et al. [10] identified a *KLC1-ALK* fusion with an unreported incidence. All of these *ALK*, *RET* and *ROS1* fusions have transforming capability.

*EGFR* and *KRAS* mutations, *ALK* translocations and *MET* amplification are found in <5% of squamous cell carcinoma, and *HER2* and *BRAF* mutations have not yet been described in this histological subtype. Squamous cell carcinoma (SCC) of the lung is a distinct molecular subtype of lung cancer potentially amenable to distinct molecularly targeted therapies. The Cancer Genome Atlas (TCGA) is conducting DNA, RNA, and miRNA sequencing along with DNA copy number profiling, quantification of mRNA expression and promoter methylation on surgically resected samples of SCC. Exome sequencing of 178 samples revealed 13 significantly mutated genes, including *TP53*, *CDKN2A*, *PTEN*, *KEAP1*, and *NFE2L2*. Apart from the near universal loss of *TP53* and *CDKN2A*, alterations in the *NFE2L2/KEAP1* and *PI3K/AKT* pathways were found in 35% and 43% of tumors analyzed. Rearrangements involving several known tumor suppressors were detected including *PTEN*, *RBI*, *NOTCH1*, *NF1* and

\*Correspondence to: Dr. S. Peters, Tel: +41-21-314-0155; Fax: +41-21-314-0200; E-mail: [solange.peters@chuv.ch](mailto:solange.peters@chuv.ch)

*CDKN2A*. *CDKN2A* loss of function was observed in 72% of specimens. Potential therapeutic targets for clinical trials with currently available drugs were identified in 127 patients (75%) [11].

This review focuses on *ALK* modification in NSCLC, but encompasses other genetic alterations that contribute to lung carcinogenesis. Many oncogene products represent targets for drug therapy, and the expanding knowledge of molecular pathways implicated in lung tumorigenesis will radically change treatment, with hope for less toxic, targeted treatment and subsequently better outcomes.

### **ALK rearrangements**

Anaplastic lymphoma kinase (*ALK*) is an orphan member of the insulin superfamily of receptor tyrosine kinases, whose normal function is poorly understood. Chromosomal rearrangements involving the *ALK* gene occur in a variety of malignancies, including anaplastic large cell lymphoma, inflammatory myofibroblastic tumors and NSCLC. To date, in NSCLC, *ALK* has three reported fusion partners: *EML4*, *KLC1* and *KIF5B*. *TFG* represents a potential fourth fusion partner which has however not been histopathologically proven until today [12]. Soda et al. [13] showed that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (*EML4*) gene and the *ALK* gene. The fusion gene results in constitutive *ALK* kinase activation, serving as a potent 'oncogenic driver' with transforming ability. The *EML4-ALK* fusion transcript could be detected in 6.7% of the 75 NSCLC patients (of Japanese ethnicity), and this alteration was mainly mutually exclusive with *EGFR* or *KRAS* mutations. *EML4-ALK*-positive tumors were mostly adenocarcinomas and tended to affect younger and more frequently never/light smokers [14]. In these tumors, *ALK* is the sole determinant of critical growth pathways, resulting in the activation of downstream canonical PI3K/AKT as well as MAPK/ERK pathways. Within the pivotal phase I/II clinical trial by Kwak et al. [15], treatment of 82 *EML4-ALK*-positive patients with the *ALK* TKI crizotinib resulted in a 57% RR and stable disease in 33% of the patients. The kinetics of clinical response was comparable to previous experiences with *EGFR* TKIs in *EGFR*-mutated NSCLC. The median PFS was 10 months, 1-year overall survival (OS) was 74% [95% confidence interval (CI) 63–82] and 2-year OS was 54% (95% CI 40–66), with a median OS not yet reached. A retrospective study by Shaw et al. [16] suggests that crizotinib might prolong OS in *ALK*-positive NSCLC, when compared with historical *ALK*-positive patients not exposed to crizotinib, who had a similar course to the general NSCLC population, suggesting that the *ALK* fusion is predictive but not prognostic. On the basis of its demonstrated efficacy and safety in phase I and II studies, crizotinib was granted accelerated approval by the Food and Drug Administration (FDA) for the treatment of advanced, *ALK*-positive NSCLC. Phase III study results are awaited, both in the second-line setting comparing crizotinib to pemetrexed or docetaxel (NCT00932893) and in the first-line setting in comparison to cisplatin and pemetrexed or carboplatin and pemetrexed (NCT01154140).

### **resistance to ALK inhibitors**

As is the case with *EGFR* TKIs, clinical benefit of crizotinib therapy is limited by the development of acquired resistance. Resistance to TKIs can be mediated either by *ALK* point mutation and/or gene amplification, or activation of bypass signaling. The most frequent resistance mutations consist in amino acid substitutions increasing kinase activity and/or hindering drug binding, as described, for example, for *EGFR* in NSCLC and BCR-ABL in chronic myeloid leukemia, respectively. In the *ALK* setting, at least eight point mutations conferring resistance to *ALK* inhibitors have already been described and most of them shown to result in cross-resistance to other *ALK* inhibitors [17, 18]. Mutations can involve the gatekeeper site within the kinase domain and interfere with inhibitor binding (L1196M), the solvent front—also altering crizotinib binding (G1202R, S1206Y), the ATP-binding pocket (G1269A) or amino acids C- or N-terminal to the  $\alpha$ C-helix—affecting ATP kinase affinity (C1156Y, L1152R, F1174L, I151Tins) [19]. More potent and irreversible inhibitors might be capable of overcoming gatekeeper resistance [20].

Another mechanism of resistance is the activation of a parallel 'side-road' or of the downstream pathways. In this situation combination targeted approaches need to be evaluated, such as in the case of *MET* amplification in *EGFR*-mutated NSCLCs. A combination of *EGFR* and *MET* inhibitors effectively overcomes this resistance in preclinical models [21]. Two recent small series have looked into the mechanisms of resistance to crizotinib and will be summarized below.

Katayama et al. analyzed biopsies of 18 patients with NSCLC who had developed secondary resistance to crizotinib and observed multiple additional genetic changes in the *ALK* gene, including *ALK* gene amplification, and further not previously described point mutations (T1151 insertion, G1202R and S1206Y) [22]. In addition, some cells harbor both *ALK* amplification and gatekeeper mutations [23]. The clinically available *ALK* inhibitors tested (CH5424802 and ASP-3026) showed distinct selectivity profiles against the various *ALK* resistance mutations, with accordingly different degrees of drug sensitivity. Doebele et al. [24] also analyzed tissue from 14 patients with *ALK*-positive NSCLC with radiological progression while on crizotinib, and identified *ALK* mutations in 4 patients, including a novel mutation G1269 which induced crizotinib resistance in cell lines. Doebele et al. also found copy number gain, defined as a more than two-fold increase in the mean rearranged gene per cell in the post-treatment biopsy compared with the pre-treatment biopsy, to be the mechanism of resistance in 2 patients out of 14. These results indicate that multiple distinct mutations in the *ALK* kinase domain can abrogate the inhibitory capacity of crizotinib. This is in sharp contrast to the *EGFR*-activating mutations, where T790M essentially represents the sole resistance mutation [25].

Nevertheless, in contrast to *EGFR* inhibitors, resistance due to secondary mutations or amplification of the drug target does not represent the predominant mechanism of acquired resistance to *ALK* inhibitors. Bypass signaling, including the *KIT* and *EGFR* pathways, has been identified as potential resistance mechanisms. Doebele et al. identified 1 patient out

of 14 with an *EGFR*-activating mutation and 2 patients with *KRAS* mutations. Nevertheless, combined inhibition of *ALK* and *EGFR* failed to induce apoptosis in resistant cell lines, a phenomenon that was also observed by Katayama et al. [22]. The *KIT* amplification-mediated resistance resembles the resistance to *EGFR* TKI mediated by *MET* amplification, with preclinical data suggesting a combination of imatinib and crizotinib may overcome this particular mechanism of resistance.

Overall, *ALK* mutations account for ~37% of acquired resistance, copy number gain for 18%; alternate oncogene activation with or without loss of *ALK* fusion gene accounts for ~36%, and unknown mechanisms for 18%. Interestingly, sometimes multiple mechanisms of resistance were observed in the same patient, e.g. an *ALK* resistance mutation and *EGFR* activation, or copy number gain and an *ALK* mutation [18]. To support this, Doebele et al. subsequently reported the analysis of 19 *ALK*-positive patients that underwent rebiopsy after progression under crizotinib therapy. Rebiopsy yielded tumor in 84% of cases, 81% of which demonstrated a plausible mechanism of resistance. 50% were *ALK* non-dominant, with 31% *ALK* kinase domain mutations and 19% *ALK* fusion gene copy number gain. 50% were *ALK*-dominant, with 31% demonstrating the emergence of alternate oncogenes (*EGFR* or *KRAS* activating mutation), and 19% unknown [26]. This potential for multiple and simultaneous resistance mechanisms has several clinical implications, affecting diagnostic evaluations as well as treatment strategies. First, new *ALK* inhibitors might effectively inhibit some resistant *ALK* fusion products, with a coexistent mechanism of resistance hampering tumor responsiveness. This clearly supports the use of combination therapy to overcome resistance. Second, the question of TKI continuation upon progression remains unresolved. Third, tumor heterogeneity, both within the primary tumor and among individual metastases, will raise the question of multiple re-biopsies. From a therapeutic standpoint, the wide array of resistance alterations will make it challenging to develop strategies to overcome *ALK* inhibitor resistance [27].

Various *ALK* inhibitors are being tested in ongoing trials. A phase I dose escalation of *ALK* TKI LDK378 (Novartis Pharmaceuticals) is recruiting patients with *ALK*-positive advanced NSCLC (NCT01283516). A phase I/II study (safety, tolerability, pharmacokinetics and preliminary antitumor activity) is testing the combined *ALK/EGFR* inhibitor AP26113 (ARIAD Pharmaceuticals) in *ALK*-positive tumors including advanced NSCLC (NCT01449461).

### heat shock protein 90 inhibitors in *ALK*-driven NSCLC

Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins. Inhibitors bind to Hsp90 and induce the proteasomal degradation of its client proteins. Tumor cells contain Hsp90 complexes in an activated conformation that facilitates malignant progression but also exhibit high-affinity to Hsp90 inhibitors and therefore represent a unique target for cancer therapeutics [28]. Clinical data have shown the efficacy of Hsp90 inhibitors in combination with *EGFR* TKIs after

progression on TKI therapy. Hsp90 inhibitors might abrogate the oncogenic switch that allows cancer cells to signal through alternative receptor tyrosine kinases. In fact, most oncogenic kinases, including *BRAF*, *MET* and *ALK*, are Hsp90 clients that are sensitive to Hsp90 inhibition [29]. Clinical evaluation of another Hsp90 inhibitor is currently in progress in unselected advanced NSCLC patients (STA 9090, Synta Pharmaceuticals Corp., NCT01031225). A single-arm phase II study is testing ganetespib (STA-9090), an Hsp90 inhibitor (Synta Pharmaceuticals Corp.) in *ALK*-positive NSCLC patients (NCT01562015). A phase II study is testing the Hsp90 inhibitor AUY922 (Novartis Pharmaceuticals) in patients with advanced NSCLC including *EGFR*-mutated or *ALK*-positive patients who have received at least two lines of prior chemotherapy (NCT01124864). Another phase II study testing IPI-204, a novel Hsp90 inhibitor (Infinity Pharmaceuticals) tested in advanced *ALK*-positive NSCLC patients, has been closed due to slow accrual (NCT01228435).

### *ROS1* rearrangements

*ROS1*, like *ALK*, is a receptor tyrosine kinase of the insulin receptor family. It has been initially identified as a potential driver mutation in an NSCLC cell line and one NSCLC patient [12]. Translocations leading to *ROS1* fusion transcripts were shown to lead to constitutive kinase activity and sensitivity to TKIs. At present, data suggest that *ROS1* is inhibited by some aspecific multiple kinase inhibitors, including crizotinib. There are currently no specific *ROS1* inhibitors in clinical trial. The clinical characteristics of patients with *ROS1* rearrangements were described by Bergethon et al. [30], who screened 1073 NSCLC patients using an *ROS1* FISH assay, mainly in the United States. Approximately 2% of NSCLC harbored *ROS1* rearrangements. As is the case with *ALK* translocations, these patients tended to be younger than the wild-type patients and were more likely to be never/light smokers. Of all never smokers screened, 6% harbored *ROS1* rearrangements. *In vitro*, crizotinib inhibits *ROS1* activity and cell proliferation. Preclinical development of *ROS1*-specific kinase inhibitors is ongoing [31]. In the phase I study PROFILE 1001, crizotinib demonstrated marked antitumor activity in 14 evaluable patients with advanced NSCLC harboring *ROS1* gene rearrangement, with 7 patients experiencing a partial response, 1 experiencing a complete response, and a 79% disease control rate at 8 weeks [15, 32].

### *BRAF* mutations

*BRAF* is a kinase that links *RAS* GTPase to downstream proteins of the *MAPK* pathway. *BRAF* lies downstream of *KRAS* and directly phosphorylates *MEK*. *BRAF* mutations cause increased kinase activity and constitutive activation of *MAPK2* and *MAPK3*. *BRAF* mutations are found in ~1–5% of NSCLC, almost exclusively adenocarcinomas [33–36]. Paik et al. [37] found 18 out of 697 screened lung adenocarcinomas to harbor a *BRAF* mutation [36]. Remarkably, all patients were current or former smokers, and there seems to be a paucity of *BRAF* mutations in non-white populations, with Sasaki et al. [35] reporting 1 out of 97 Japanese patients with lung adenocarcinoma harboring a *BRAF* mutation. Marchetti et al.

screened 1046 NSCLC patients and found BRAF mutations in 4.9% of adenocarcinomas and 0.3% of squamous NSCLC. The mutations found in NSCLC are distinct from the melanoma setting: whereas BRAF-mutated melanoma harbors a V600E amino acid substitution in more than 80% of cases, NSCLC harbors non-V600E mutations, distributed in exons 11 and 15, in ~40%–50% of cases. In Marchetti's publication, all non-V600E mutations (2%) detected in adenocarcinomas were found in smokers and V600E mutations (2.8%) were substantially more frequent in females and in never smokers. In this series, follow-up data were available for the 331 resected lung carcinomas, showing that patients with V600E BRAF mutations had more aggressive tumor histotype, characterized by micropapillary features and associated with shorter median disease-free survival and OS, while no prognostic impact was found for the non-V600E mutations [36]. Interestingly, mutations in BRAF were mutually exclusive with EGFR and KRAS mutations, and ALK rearrangements. Due to the large predominance of V600E mutations in melanoma, current drugs targeting BRAF such as vemurafenib have been tailored to have specific activity against V600E mutant kinase. Their activity against other BRAF mutations found in NSCLC, such as G469A (39%) and D594G (11%) is unknown. Preclinical data suggest that non-V600E mutated BRAF kinases are resistant to vemurafenib [38]. Conversely, the CRAF inhibitor sorafenib was found to be ineffective against the V600E mutant isoform, but might have increased activity against other BRAF mutants that have increased CRAF activity [39]. In addition, there are preclinical data, suggesting that BRAF mutations might predict sensitivity of NSCLC cells to MEK inhibitors [40].

Clinical data on efficacy and resistance to BRAF pathway inhibitors are not yet available. According to preclinical data, amplification of BRAF or activation of downstream pathway components such as activating MEK mutations, or signaling through other RAF family members, might be among the main mechanisms of resistance [41]. It has been observed that colon cancer patients harboring V600E BRAF mutations show only a very limited response to vemurafenib [42]. In this setting, BRAF inhibition leads to rapid feedback activation of EGFR, and blockade of EGFR with cetuximab, gefitinib or erlotinib shows strong synergy with BRAF V600E inhibition *in vitro* [43].

A phase I study testing the multiple RAF kinase inhibitor (including CRAF, BRAF and the activated mutant BRAF V600E) XL281 (BMS-908662, Bristol-Myer Squibb) has been completed (NCT01086267) and results are awaited. AZD6244, a novel and highly selective MEK inhibitor is in phase II clinical trial for patients with solid tumors harboring a BRAF mutation (NCT00888134), and a phase II randomized trial versus pemetrexed in patients with advanced NSCLC in the second or third line has been completed, with results pending (NCT00372788). For the same compound, data are awaited from a phase II trial comparing its combination with docetaxel versus docetaxel alone in patients with advanced NSCLC with mutated KRAS (NCT00372788). The BATTLE-2 Program, a biomarker-integrated targeted therapy study in previously treated patients with advanced NSCLC, also tests this compound in combination with MK2206 (Merck), an AKT inhibitor (NCT01248247). And finally, an ongoing phase II

study evaluates the selective BRAF kinase inhibitor GSK2118436 (GlaxoSmithKline) in patients with advanced NSCLC harboring BRAF mutations (NCT01336634).

### KRAS mutations

Activating mutations in codons 12 and 13 of the KRAS oncogene occur in ~24% of lung adenocarcinomas and are mutually exclusive to EGFR mutations, HER2 mutations, ALK rearrangements and BRAF mutations [4]. KRAS mutations seem to occur early in the development of smoking-related carcinomas [44]. Cappuzzo and colleagues carried out a prospective molecular marker analysis of EGFR and KRAS in a large sample of patients randomly assigned to placebo or erlotinib maintenance therapy after first-line chemotherapy. KRAS mutations seemed to be prognostic for reduced PFS, regardless of treatment received [45]. There is currently no drug available capable of inhibiting KRAS directly, and current strategies focus on potential targets downstream of KRAS in the RAS/RAF/MEK pathway. Sorafenib, a weak RAF inhibitor, showed efficacy in KRAS mutant NSCLC according to a brief report by Smit et al. [46], with a partial response in 3 out of 10 patients and stable disease in 6 out of 10 patients, with a median PFS of 3 months. Sorafenib also showed efficacy in the BATTLE trial, a phase II adaptive randomized trial, where KRAS mutant NSCLC on sorafenib showed a lower progression rate at 8 weeks when compared with the whole study population of 244 patients [47]. An ongoing phase II study is testing the MEK inhibitor GSK1120212 (GlaxoSmithKline) versus docetaxel in the second-line setting in advanced NSCLC patients with specific mutations in the KRAS signaling pathway (including KRAS) (NCT01362296).

### HER2 mutations

HER2 (or ERBB-2) is a member of the EGFR family of receptor tyrosine kinases. It does not have a known ligand and is activated by homodimerization or heterodimerization with other members of the HER family. HER2 activates the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway. HER2 overexpression or gene amplification is associated with sensitivity to trastuzumab and lapatinib in breast cancer. In a meta-analysis of 40 published studies, HER2 overexpression assessed by immunohistochemistry (IHC) was shown to be a marker of poor prognosis in NSCLC, with a hazard ratio of 1.48 (95% CI 1.22–1.80) and 1.95 (95% CI 1.56–2.43) in adenocarcinomas specifically. No prognostic value was found in squamous cell carcinomas. HER2 amplification determined by FISH was not related to prognosis [48]. In the lung cancer setting, amplification was found in 2–23% of the patients, while HER2 mutations were found in 2% of lung adenocarcinomas [49]. HER2 mutations consist of insertions in exon 20, leading to constitutive activation of the receptor, with downstream activation of AKT and MEK [50]. *In vitro*, cells harboring these mutations are sensitive to TKIs targeting HER2 and EGFR such as lapatinib [51] but are resistant to TKIs targeting EGFR alone. This is the case irrespective of the EGFR mutational status (i.e. including the small number of tumors harboring both EGFR and HER2 mutations), the activating signals being executed through the HER2 kinase [49].

In preclinical models of NSCLC trastuzumab has additive or synergistic antitumor activity in combination with various cytotoxic agents [52]. Trastuzumab has been tested in advanced NSCLC patients overexpressing *HER2* in a phase II trial, in combination with cisplatin and gemcitabine (NCT00016367), and failed to show survival benefit in all *HER2* IHC-positive lung cancers. Nevertheless, 80% of the patients with IHC 3+ disease on study treatment were still alive at 6-month follow-up, compared with 64% of the overall population, and an RR of 83% and a median PFS of 8.5 months were observed in the six trastuzumab-treated patients with *HER2* 3+ or FISH-positive NSCLC [53]. In *HER2*-amplified NSCLC, there seems to be no benefit from lapatinib [54]. A case report from 2006 describes a female non-smoker with metastatic adenocarcinoma resistant to cisplatin, taxane and EGFR TKI therapy, with a tumor carrying an exon 20 mutation (G776L) and *HER2* amplification responding to trastuzumab given weekly together with paclitaxel [55]. A single-arm trial of the EGFR/*HER2* dual inhibitor BIBW 2992 (afatinib) showed responses in 3/3 assessable patients (out of 5 identified) with adenocarcinoma harboring *HER2* activating mutations, even in the context of resistance to other EGFR- or *HER2*-targeted compounds [56].

Trastuzumab is currently being tested alone, in IHC-positive or, respectively, *HER2*-mutated or -amplified NSCLC (NCT00004883 and NCT00758134) and in combination with carboplatin and paclitaxel. Results are pending. Lapatinib has been tested in molecularly unselected advanced NSCLC patients, including one trial that has been stopped for futility after interim analysis (NCT00073008). Pertuzumab has been tested in a phase II trial in advanced NSCLC patients with *HER2* activation (NCT00063154). Results are pending. More trials investigating afatinib in other advanced NSCLC patients, including in combination with EGFR TKIs, are ongoing.

### **PIK3CA mutations**

*PIK3CA* mutations regenerate phosphatidylinositol-3-phosphate, which is a key mediator between growth factor receptors and downstream signaling pathways. In NSCLC, *PIK3CA* mutations affect most frequently the catalytic domain encoded in exon 9 and are found in ~2% of NSCLC, as frequently in adenocarcinoma as in squamous cell carcinoma [57]. *PIK3CA* mutations induce oncogenic cellular transformation [58]. Amplification of *PIK3CA* has also been observed in NSCLC, particularly in squamous cell carcinoma, but the oncogenic potential of *PIK3CA* amplification alone has not yet been shown [59]. Chaft et al. reported 23 out of 1125 patients harboring *PIK3CA* mutations, 16 (70%) of which had coexisting mutations in other oncogenes: 10 *KRAS*, 1 *BRAF*, 1 *ALK* rearrangement and 3 *EGFR* exon 19 deletions [60]. This is in sharp contrast to the mutual exclusiveness of driver oncogene mutations found in lung adenocarcinomas harboring *EGFR*, *KRAS* or *ALK* transformations. In their sample, the presence of coexisting oncogene mutations was associated with an inferior outcome, with only one patient having received an experimental agent targeting *PIK3CA*. Cell lines with *PIK3CA* mutations are sensitive to downstream inhibitors such as mTOR inhibitors, but this sensitivity is abrogated by coexistent

*KRAS* mutation [61]. Preclinical data actually suggest that coexisting *KRAS* and *PIK3CA* mutations are associated with resistance to PI3K/AKT/mTOR inhibitors.

The oral PI3K inhibitor BKM120 (Novartis Pharmaceuticals) is being tested in a phase II trial in pretreated advanced NSCLC patients with activated PI3K pathway (NVT01297491). The same compound is also being tested in combination with erlotinib in the setting of resistance to EGFR TKIs (NCT01487265). Another oral specific PI3K inhibitor, GDC0941 (Genentech), is being tested in a phase Ib trial in combination with carboplatine/paclitaxel ± bevacizumab or cisplatin/pemetrexed/bevacizumab in unselected patients with advanced NSCLC (NCT00974584).

### **MET amplification and point mutations**

The *MET* oncogene encodes hepatocyte growth factor (HGF) receptor, a transmembrane receptor with tyrosine kinase activity. Its amplification has been reported in 1.4% of lung adenocarcinomas in a Japanese population and 21% of NSCLC in a European population including squamous cell carcinomas [62, 63]. *MET* amplification has transforming capacity, being sufficient to drive the proliferation of cancer cells and development of metastasis in a mouse melanoma model [64]. *MET* amplification is observed as a mechanism of resistance in ~20% of the patients with activating *EGFR* mutations progressing under EGFR TKI [65]. Point mutations in the kinase domain of *MET* are rare in NSCLC [66, 67]. While their prevalence is low, their potential for causing disease progression is significant [68], and when used to replace endogenous *MET* in the mouse germline, these mutations cause a variety of tumors including carcinomas of various tissues of origin [69]. In NSCLC, most of *MET* mutations are located in the extracellular sema domain and the juxtamembrane domain of *MET*, with a preclinical demonstrated potential to affect ligand binding, receptor activation and receptor turnover.

The *MET* pathway can be inhibited by monoclonal antibodies against HGF or its receptor or by *MET* TKIs [70]. AMG102 (Amgen), a human monoclonal antibody that binds and neutralizes HGF/scatter factor (SF), is being tested with erlotinib in a phase I/II trial in pretreated patients with advanced NSCLC (NCT01233687).

Interestingly, two randomized phase II trials of a *MET* monoclonal antibody (onartuzumab, Genentech) and a *MET*-specific TKI tivantinib together with erlotinib versus erlotinib alone showed promising results in unselected pretreated NSCLC patients and are now being tested in a phase III trial [71]. Onartuzumab is being tested in various settings including this randomized phase III trial which is testing onartuzumab or placebo in combination with erlotinib in pretreated patients with advanced *MET* IHC-positive NSCLC (NCT01456325); another randomized phase III trial is testing onartuzumab or placebo in combination with carboplatin/cisplatin and paclitaxel in untreated patients with advanced squamous cell carcinoma (NCT01519804); a randomized phase II trial is testing onartuzumab or placebo in combination with bevacizumab/carboplatine/paclitaxel or cisplatin/pemetrexed (NCT01496742). Tivantinib (ARQ197, Daiichi Sankyo) is

tested in a phase III trial versus placebo in combination with erlotinib in advanced non-squamous NSCLC (NCT01244191) [72]. Besides crizotinib, a potent MET inhibitor, various other small-molecule MET inhibitors are being tested in NSCLC, including GSK13693089 (foretinib, a MET/VEGFR2 inhibitor, GlaxoSmithKline) and XL184 (cabozantinib, a MET/VEGFR2 inhibitor, Exelixis), even if, to date, a predictive biomarker for MET inhibitor sensitivity remains to be defined.

## conclusion

The discovery of EGFR mutations has opened the era of targeted therapy in NSCLC, shifting treatment from platinum-based chemotherapy for all fit patients to molecularly personalized therapy. The greatest improvements in outcome are obtained by targeting the ‘driver genetic alteration’ of each specific molecularly defined subset, rather than targeted therapy of unselected patients. The identification of the key molecular abnormality will thus become crucial, even if numerous very small subsets of tumors will have to be identified.

Acquired resistance has emerged as a major hurdle preventing targeted therapy from having a substantial long-term impact on outcome beyond their initial benefit. The understanding of these mechanisms will hopefully allow a better sequencing and optimal combination of targeted agents in each biologically defined setting. Resistance mutations may be overcome with more potent and/or irreversible inhibitors capable of blocking mutated targets. Combination therapies will most likely be the key to overcome resistance mediated by activation of parallel or downstream pathways. Several other mechanisms of drug resistance, such as drug efflux by antiporter efflux pumps, as well as anti-apoptotic mechanisms have the potential to limit drug efficacy and need to be further explored.

Beyond oncogenic activation, other genetic alterations not encoded by the DNA sequences, referred to as epigenetic changes, also represent potential therapeutic targets. As opposed to genetic lesions, the epigenetic changes are potentially reversible by a number of small molecules such as histone deacetylases, which are, however, beyond the scope of this review [73].

In conclusion, targeted therapies hold promise for improved outcome in advanced NSCLC patients, even after the development of acquired resistance. This, however, will demand the incorporation of broad genotyping of NSCLC into the clinic as a standard of care, as well as successive repeated and potentially multisite biopsies.

## disclosure

The authors have declared no conflicts of interest.

## references

- Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2008; 26: 3543–3551.
- Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009; 361: 947–957.
- Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012; 13: 239–246.
- Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol* 2011; 22: 2616–2624.
- Sun Y, Ren Y, Fang Z et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *J Clin Oncol* 2010; 28: 4616–4620.
- Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). *J Clin Oncol* 2011; 29(suppl) (abstr. CRA7506).
- Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med* 2012; 18: 378–381.
- Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat Med* 2012; 18: 375–377.
- Capelletti M, Lipson D, Otto G et al. Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens. *J Clin Oncol* 2012; 30(suppl) (abstr. 7510).
- Togashi Y, Soda M, Sakata S et al. KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only. *PLoS One* 2012; 7: e31323.
- Govindan R, Hammerman PS, Hayes DN et al. Comprehensive genomic characterization of squamous cell carcinoma of the lung. *J Clin Oncol* 2012; 30 (suppl) (abstr. 7006).
- Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 2007; 131: 1190–1203.
- Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007; 448: 561–566.
- Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009; 27: 4247–4253.
- Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010; 363: 1693–1703.
- Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol* 2011; 12: 1004–1012.
- Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010; 363: 1734–1739.
- Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 2011; 71: 6051–6060.
- Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. *Sci Transl Med* 2012; 4: 120ps122.
- Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. *Future Oncol* 2011; 7: 817–825.
- Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell* 2010; 17: 77–88.
- Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med* 2012; 4: 120ra117.
- Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci USA* 2011; 108: 7535–7540.
- Doebbele RC, Pilling AB, Aisner DL et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. *Clin Cancer Res* 2012; 18: 1472–1482.
- Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005; 2: e73.
- Doebbele RC, Aisner DL, Le AT et al. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. *J Clin Oncol* 2012; 30(suppl) (abstr. 7504)
- Heuckmann JM, Holzel M, Sos ML et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. *Clin Cancer Res* 2011; 17: 7394–7401.

28. Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. *Nature* 2003; 425: 407–410.
29. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. *Nat Rev Cancer* 2010; 10: 537–549.
30. Bergethon K, Shaw AT, Ignatius Ou SH et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. *J Clin Oncol* 2012; 30: 863–870.
31. El-Deeb IM, Park BS, Jung SJ et al. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors. *Bioorg Med Chem Lett* 2009; 19: 5622–5626.
32. Shaw AT, Camidge DR, Engelman JA et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. *J Clin Oncol* 2012; 30(suppl) (abstr. 7508).
33. Naoki K, Chen TH, Richards WG et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. *Cancer Res* 2002; 62: 7001–7003.
34. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. *Nature* 2002; 417: 949–954.
35. Sasaki H, Kawano O, Endo K et al. Uncommon V599E BRAF mutations in Japanese patients with lung cancer. *J Surg Res* 2006; 133: 203–206.
36. Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. *J Clin Oncol* 2011; 29: 3574–3579.
37. Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol* 2011; 29: 2046–2051.
38. Yang H, Higgins B, Kolinsky K et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. *Cancer Res* 2010; 70: 5518–5527.
39. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 2004; 116: 855–867.
40. Pratilas CA, Hanrahan AJ, Halilovic E et al. Genetic predictors of MEK dependence in non-small cell lung cancer. *Cancer Res* 2008; 68: 9375–9383.
41. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. *Oncotarget* 2011; 2: 336–346.
42. Yang H, Higgins B, Kolinsky K et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. *Cancer Res* 2012; 72: 779–789.
43. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. *Nature* 2012; 483: 100–103.
44. Ahrendt SA, Decker PA, Alawi EA et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer* 2001; 92: 1525–1530.
45. Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2011; 29: 4113–4120.
46. Smit EF, Dingemans AM, Thunnissen FB et al. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. *J Thorac Oncol* 2010; 5: 719–720.
47. Printz C. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. *Cancer* 2010; 116: 3307–3308.
48. Liu L, Shao X, Gao W et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. *J Thorac Oncol* 2010; 5: 1922–1932.
49. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. *Cancer Res* 2005; 65: 1642–1646.
50. Shimamura T, Ji H, Minami Y et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV\_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. *Cancer Res* 2006; 66: 6487–6491.
51. Wang SE, Narasanna A, Perez-Torres M et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell* 2006; 10: 25–38.
52. Bunn PA, Jr., Helfrich B, Soriano AF et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. *Clin Cancer Res* 2001; 7: 3239–3250.
53. Gatzemeier U, Groth G, Butts C et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol* 2004; 15: 19–27.
54. Ross HJ, Blumenschein GR, Jr., Aisner J et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. *Clin Cancer Res* 2010; 16: 1938–1949.
55. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. *N Engl J Med* 2006; 354: 2619–2621.
56. De Greve J, Teugels E, Geers C et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. *Lung Cancer* 2012; 76: 123–127.
57. Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. *Lung Cancer* 2006; 54: 209–215.
58. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. *Proc Natl Acad Sci USA* 2006; 103: 1475–1479.
59. Kawano O, Sasaki H, Okuda K et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. *Lung Cancer* 2007; 58: 159–160.
60. Chaft JE, Arcila ME, Paik PK et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma—rationale for comprehensive mutation profiling. *Mol Cancer Ther* 2012; 11: 485–491.
61. Di Nicolantonio F, Arena S, Tabernero J et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. *J Clin Invest* 2010; 120: 2858–2866.
62. Onozato R, Kosaka T, Kuwano H et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. *J Thorac Oncol* 2009; 4: 5–11.
63. Beau-Faller M, Ruppert AM, Voegeli AC et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. *J Thorac Oncol* 2008; 3: 331–339.
64. Otsuka T, Takayama H, Sharp R et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. *Cancer Res* 1998; 58: 5157–5167.
65. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci USA* 2007; 104: 20932–20937.
66. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008; 455: 1069–1075.
67. Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. *Cancer Res* 2005; 65: 1479–1488.
68. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. *Nat Rev Cancer* 2012; 12: 89–103.
69. Graveel C, Su Y, Koeman J et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. *Proc Natl Acad Sci USA* 2004; 101: 17198–17203.
70. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. *Nat Rev Clin Oncol* 2012; 9: 314–326.
71. Sequist LV, von Pawel J, Garmey EG et al. Randomized phase II study of erlotinib plus vandetanib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. *J Clin Oncol* 2011; 29: 3307–3315.
72. Scagliotti GV, Novello S, Schiller JH et al. Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Vandetanib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer. *Clin Lung Cancer* 2012 March 23 [epub ahead of print], doi: 10.1016/j.clcc.2012.01.003.
73. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. *Eur J Pharmacol* 2009; 625: 131–142.